Key Points
- Mudit Jain, a CVRx director, bought 46,800 shares on Feb. 20 at an average price of $6.36 (≈$297,648), raising his direct stake to 980,183 shares (a 5.01% increase); the purchase was disclosed in an SEC Form 4.
- CVRx missed EPS estimates in the latest quarter (reported ($0.46) vs. ($0.42) expected) while slightly beating revenue ($16.02M vs. $15.75M), and remains unprofitable with a negative ROE and net margin; analysts forecast -1.91 EPS for the year.
- The stock trades near $6.79 with a $178.6M market cap and a one‑year range of $4.30–$14.04; it carries a consensus "Moderate Buy" rating and a $11.20 average target, with ~75% of shares held by institutional investors.
CVRx, Inc. (NASDAQ:CVRX - Get Free Report) Director Mudit Jain acquired 46,800 shares of the stock in a transaction dated Friday, February 20th. The stock was bought at an average cost of $6.36 per share, with a total value of $297,648.00. Following the completion of the purchase, the director directly owned 980,183 shares in the company, valued at approximately $6,233,963.88. The trade was a 5.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
CVRx Price Performance
Shares of CVRx stock opened at $6.79 on Tuesday. The stock has a market cap of $178.64 million, a price-to-earnings ratio of -3.31 and a beta of 1.31. The company has a debt-to-equity ratio of 1.26, a quick ratio of 6.72 and a current ratio of 7.63. The stock has a 50 day moving average price of $6.80 and a 200-day moving average price of $8.00. CVRx, Inc. has a one year low of $4.30 and a one year high of $14.04.
CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). The company had revenue of $16.02 million during the quarter, compared to the consensus estimate of $15.75 million. CVRx had a negative return on equity of 99.32% and a negative net margin of 94.10%. Equities analysts expect that CVRx, Inc. will post -1.91 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. AlphaQuest LLC lifted its holdings in shares of CVRx by 114.6% in the 2nd quarter. AlphaQuest LLC now owns 13,106 shares of the company's stock worth $77,000 after buying an additional 6,998 shares during the period. Corton Capital Inc. purchased a new position in shares of CVRx during the second quarter valued at $176,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of CVRx by 120.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,032 shares of the company's stock valued at $171,000 after acquiring an additional 15,837 shares in the last quarter. FourWorld Capital Management LLC lifted its stake in CVRx by 563.7% in the second quarter. FourWorld Capital Management LLC now owns 124,123 shares of the company's stock worth $730,000 after acquiring an additional 105,422 shares during the period. Finally, R Squared Ltd purchased a new stake in CVRx in the fourth quarter worth about $74,000. 75.27% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages recently commented on CVRX. Weiss Ratings reiterated a "sell (d-)" rating on shares of CVRx in a report on Monday, December 29th. Canaccord Genuity Group dropped their target price on CVRx from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, February 13th. Finally, Cantor Fitzgerald upgraded CVRx to a "strong-buy" rating in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, CVRx presently has an average rating of "Moderate Buy" and a consensus target price of $11.20.
Get Our Latest Research Report on CVRx
CVRx Company Profile
(
Get Free Report)
CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company's flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body's natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.
The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
